SCA
AXSM icon

Snowden Capital Advisors’s Axsome Therapeutics AXSM Stock Holding History

Snowden Capital Advisors’s Portfolio AXSM Stock Details AXSM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$396K Buy
1,619
+13
+0.8% +$2.82K 0.01% 941
2026
Q1 		$271K Sell
1,606
-32
-2% -$5.53K 0.01% 1073
2025
Q4 		$299K Buy
+1,638
New +$229K 0.01% 1044

Other funds holding AXSM

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Snowden Capital Advisors's AXSM Position: Q2 2026 in Review

Snowden Capital Advisors increased its Axsome Therapeutics (AXSM) stake by 0.81% in Q2 2026, buying an estimated $2.82K and bringing the position to 1,619 shares worth $396K. The position accounts for 0.01% of the portfolio, ranked #941.

Snowden Capital Advisors first reported a position in AXSM in Q4 2025 and has held it in 3 quarters since. 506 funds tracked by Wall St. Rank hold AXSM as of Q2 2026.

  • Snowden Capital Advisors held 1,619 shares of Axsome Therapeutics worth $396K as of Q2 2026.
  • Snowden Capital Advisors bought 13 Axsome Therapeutics shares in Q2 2026, an estimated $2.82K.
  • Axsome Therapeutics made up 0.01% of Snowden Capital Advisors's portfolio in Q2 2026, its #941 holding.
  • Snowden Capital Advisors first reported a position in Axsome Therapeutics in Q4 2025 and has held it in 3 quarters since.
  • 506 funds tracked by Wall St. Rank held Axsome Therapeutics as of Q2 2026.

Based on Snowden Capital Advisors's 13F filing for Q2 2026, filed 13 Aug 2026.